Immunoglobulin chimeric monomer-dimer hybrids

Details Immunoglobulin chimeric monomer-dimer hybrids Immunoglobulin chimeric monomer-dimer hybrids

2008-07-29

2008-07-29

Campell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C530S387100, C530S387300, C530S391700, C530S402000

Reexamination Certificate

active

10841250

ABSTRACT:
The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

REFERENCES:
patent: 3941763 (1976-03-01), Sarantakis
patent: 4695623 (1987-09-01), Stabinsky
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4897471 (1990-01-01), Stabinsky
patent: 5077204 (1991-12-01), Brake et al.
patent: 5093246 (1992-03-01), Cech et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5162220 (1992-11-01), Oshima et al.
patent: 5175096 (1992-12-01), Hook et al.
patent: 5189015 (1993-02-01), Hook et al.
patent: 5234830 (1993-08-01), Oshima et al.
patent: 5258498 (1993-11-01), Huston et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5482858 (1996-01-01), Huston et al.
patent: 5579277 (1996-11-01), Bolognsi et al.
patent: 5585089 (1996-11-01), Kelly
patent: 5591573 (1997-01-01), Whalen et al.
patent: 5605689 (1997-02-01), Ammann
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648240 (1997-07-01), Ammann et al.
patent: 5723125 (1998-03-01), Chang et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5807706 (1998-09-01), Carter et al.
patent: 5808029 (1998-09-01), Brockhaus et al.
patent: 5885821 (1999-03-01), Magota et al.
patent: 5910573 (1999-06-01), Pluckthun et al.
patent: 6013263 (2000-01-01), Barney et al.
patent: 6015881 (2000-01-01), Kang et al.
patent: 6017536 (2000-01-01), Barney et al.
patent: 6030613 (2000-02-01), Blumberg et al.
patent: 6060065 (2000-05-01), Barney et al.
patent: 6068973 (2000-05-01), Barney et al.
patent: 6086875 (2000-07-01), Blumberg et al.
patent: 6093799 (2000-07-01), Li et al.
patent: 6184344 (2001-02-01), Kent et al.
patent: 6228983 (2001-05-01), Barney et al.
patent: 6281331 (2001-08-01), Kang et al.
patent: 6310180 (2001-10-01), Tam
patent: 6310183 (2001-10-01), Johannessen et al.
patent: 6326468 (2001-12-01), Canne et al.
patent: 6329176 (2001-12-01), Woldike et al.
patent: 6469136 (2002-10-01), Bray et al.
patent: 6475491 (2002-11-01), Johnson et al.
patent: 6485726 (2002-11-01), Blumberg et al.
patent: 6518013 (2003-02-01), Barney et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 2002/0081664 (2002-06-01), Lo et al.
patent: 2002/0106374 (2002-08-01), Olson et al.
patent: 2003/0053984 (2003-03-01), Tschopp et al.
patent: 2003/0119727 (2003-06-01), Dennis et al.
patent: 2003/0180287 (2003-09-01), Gambotz et al.
patent: 2003/0235536 (2003-12-01), Blumberg et al.
patent: 2004/0077022 (2004-04-01), Feige et al.
patent: 2005/0027109 (2005-02-01), Mezo et al.
patent: 2005/0037941 (2005-02-01), Bitonti et al.
patent: 0 325 262 (1989-07-01), None
patent: 2 641 468 (1990-07-01), None
patent: WO 88/09810 (1988-12-01), None
patent: WO 89/10134 (1989-02-01), None
patent: WO 90/11364 (1991-10-01), None
patent: WO 92/10209 (1992-06-01), None
patent: WO 93/11162 (1993-06-01), None
patent: WO 00/18881 (2000-05-01), None
patent: WO 01/02439 (2001-01-01), None
patent: WO 01/36637 (2001-05-01), None
patent: WO 01/58935 (2001-08-01), None
patent: WO 01/91780 (2001-12-01), None
patent: WO 02/18417 (2002-03-01), None
patent: WO 02/46208 (2002-06-01), None
patent: WO 02/089828 (2002-11-01), None
patent: 03/077834 (2003-09-01), None
patent: WO 03/077834 (2003-09-01), None
patent: WO 2004/03176 (2004-01-01), None
patent: WO 2004/006962 (2004-01-01), None
patent: WO 2004/101740 (2004-11-01), None
patent: WO 2005/001025 (2005-01-01), None
US 6,020,459, 02/2000, Barney et al. (withdrawn)
Baru et al. Liposome-encapsulated DNA-mediated gene transfer and synthesis of human factor IX in mice. Gene 1995, vol. 161, p. 143-150.
International Search Report for PCT/US04/14064 dated Apr. 6, 2006.
Ghetie et al., “Multiple Roles for the Major Histocompatibility Complex Class I-Related Receptor FcRn,”Annu. Rev. Immunol., 18:739-766 (2000).
Jelesarov et al., “Thermodynamic Characterization of the Coupled Folding and Association of Heterodimeric Coiled Coils (Leucine Zippers),”J. Mol. Biol., 263:344-358 (1996).
Swaminathan et al., “Affinity Purification of Recombinant Interferon-α on a Mimetic Ligand Adsorbent,”Protein Expression and Purification, 15:236-242 (1999).
Aruffo et al., “CD44 Is the Principal Cell Surface Receptor for Hyaluronate,”Cell61:1303 (1990).
Ashkenazi et al., “Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin,”Proc. Natl. Acad. Sci. USA88:10535 (1991).
Bennett et al., “Extracellular Domain-IgG Fusion Proteins for Three Human Natriuretic Peptide Receptors,”J. Biol. Chem. 266:23060 (1991).
Brennan et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1Fragments,”Science229:81 (1985).
Byrn et al., “Biological properties of a CD4 immunoadhesin,”Natur, 344:667 (1990).
Capon et al., “Designing CD4 immunoadhesins for AIDS therapy,”Nature337:525 (1989).
Chalupny et al., “T-cell activation molecule 4-1BB binds to extracellular matrix proteins,”Proc. Natl. Acad. Sci. USA89:10360 (1992).
Dawson et al., “Synthesis of Native Proteins by Chemical Ligation,”Annu. Rev. Biochem. 69:923 (2000).
Gascoigne et al., “Secretion of a chimeric T-cell receptor-immunoglobulin protein,”Proc. Natl. Acad. Sci. USA84:2936 (1987).
Kostelny et al., “Formation of a bispecific antibody by the use of leucine zippers,”J. Immunol. 148(5):1547 (1992).
Kurschner et al., “Construction, Purification, and Characterization of New InterferonY(IFNy) Inhibitor Proteins,”J. Biol. Chem267:9354 (1992).
Lesslauer et al., “Recombinant soluble tumor necrosis factor receptor proteins mice from lipopolysaccharide-induced lethality,”Eur. J. Immunol. 21:2883 (1991).
Linsley et al., “Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation,”J. Exp. Med173:721 (1991).
Linsley et al., “CTLA-4 Is a Seond Receptor for the B Cell Activation Antigen B7,”J. Exp. Med. 174:561 (1991).
Louis et al., “Design and Properties of NCCG-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion Inhibitory Activity,”J. Biol. Chem. 276:(31)29485 (2001).
Peppel et al., “A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity,”J. Exp. Med. 174:1483 (1991).
Ridgeway and Gorman, “Expression and Activity of IgE Receptor Alpha Chain-IgG Chimeric Molecules,”J. Cell. Biol115, Abstract No. 1448 (1991).
Root et al., “Protein Design of an HIV-1 Entry Inhibitor,”Science291:884 (2001).
Stamenkovic et al., “The B Lymphocyte Adhesion Molecule CD22 Interacts with Leukocyte Common Antigen CD45RO on T Cells and α2-6 Sialytransferase, CD75, on B Cells,”Cell66:1133 (1991).
Traunecker et al., “Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules,”Nature339:68 (1989).
Watson et al., “A Homing Receptor-IgG Chimera as a Probe for Adhesive Ligands of Lymph Node High Endothelial Venules,”J. Cell. Biol. 110:2221 (1990).
Watson et al., “Neutrophil influx into an inflammatory site inhibited by a soluble homing receptor-IgG chimaera,”Nature349:164 (1991).
Zettmeissl et al., “Expression and Characterization of Human CD4: Immunoglobulin Fusion Proteins,”DNA Cell Biol. USA9:347 (1990).
Zheng et al., “Administration of Noncytolytic IL-10/Fc in Murine Models of Lipopolysaccha

Affiliated with

Also associated with

Rating

Immunoglobulin chimeric monomer-dimer hybrids does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunoglobulin chimeric monomer-dimer hybrids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoglobulin chimeric monomer-dimer hybrids will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3921963